Candel Therapeutics Q1 net income $7.4M; cash runway into Q1 2027; CAN-2409 BLA on track

Candel Therapeutics, Inc.

2025-Q1 EPS reported $0.13

Net income of $7.4M in Q1 2025 vs net loss of $8.2M in Q1 2024, driven by warrant liability fair value change.
Cash and equivalents $92.2M as of March 31, 2025; expected to fund operations into Q1 2027.
CAN-2409 phase 3 prostate cancer meets primary endpoint; BLA submission expected Q4 2026.
CAN-2409 in borderline resectable PDAC: mOS 31.4 months vs 12.5 months control in phase 2a.
CAN-2409 in NSCLC (ICI-progressive): mOS 21.5 months vs 9.8–11.8 months standard of care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.